AstraZeneca H1 2026: Revenue Climbs 6%, Core EPS Rises 11%, Guidance Reaffirmed

summarizeSummary

H1 2026 results show 6% CER revenue growth and 11% Core EPS growth, with guidance reaffirmed. The pipeline delivered multiple positive readouts and approvals, while new licensing deals add to the growth story.

check_boxKey Events · Earnings and Guidance · AZN

• H1 Revenue +6% CER to $30.7B

  Total Revenue reached $30,672M, with Oncology up 15% CER and Rare Disease up 11% CER, offsetting a 12% CER decline in CVRM due to Farxiga LOE and China VBP.

• Core EPS +11% CER to $5.21

  Core operating profit grew 11% CER, driving Core EPS to $5.21. Reported EPS was $3.60, up 3% CER, impacted by higher amortization and impairment charges.

• FY 2026 Guidance Reaffirmed

  Management expects mid-to-high single-digit Total Revenue growth and low double-digit Core EPS growth at CER, with a Core tax rate of 18-22%.

• Pipeline Delivers Multiple Wins

  Six positive Phase III readouts (including Imfinzi in VOLGA and NILE, sone-ve in CLARITY-Gastric01) and eight first approvals in major markets (including Baxfendy for hypertension).

auto_awesomeAnalysis · AZN · Life Sciences

A solid first half saw Total Revenue advance 6% at constant exchange rates to $30.7 billion, fueled by double-digit growth in Oncology and Rare Disease. Core EPS jumped 11% to $5.21, and the full-year outlook was reaffirmed—mid-to-high single-digit revenue growth and low double-digit Core EPS expansion. The pipeline's strength was on display with multiple Phase III wins and regulatory approvals, helping to counter headwinds from Farxiga's US loss of exclusivity and China VBP. Two new licensing deals underscore continued investment in growth: $600M upfront for Dizal's Zegfrovy and $200M upfront for Sino Biopharmaceutical's TQC3721. Reflecting confidence, the interim dividend was raised 3 cents to $1.06 per share.